Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART

AIDS

Volumn 21, Issue 12, 2007, Pages 1607-1615

  Chiappini, Elena ^a   Galli, Luisa ^a   Tovo, Pier Angelo ^b   Gabiano, Clara ^b   Lisi, Catiuscia ^a   Gattinara, Guido Castelli ^c   Esposito, Susanna ^d   Viganò, Alessandra ^e   Giaquinto, Carlo ^f   Rosso, Raffaella ^g   Guarino, Alfredo ^h   De Martino, Maurizio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Children; Combined antiretroviral therapy; HIV infection

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BACTERIAL INFECTION; CANCER; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MORBIDITY; OPPORTUNISTIC INFECTION; PERINATAL INFECTION; PNEUMONIA; POISSON DISTRIBUTION; POPULATION RESEARCH; PRIORITY JOURNAL; SURVIVAL RATE;

AIDS DEMENTIA COMPLEX; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV WASTING SYNDROME; HIV-1; HUMANS; INFANT; ITALY; MALE; PNEUMONIA, BACTERIAL;

EID: 34447578624     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32823ecf5b     Document Type: Article

References (23)

1. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135:17-26.
2. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20:741-749.
3. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000; 284:190-197.
4. Centers for Disease Control and Prevention. Epidemiology of HIV/AIDS: United States, 1981-2005. MMWR Morb Mortal Wkly Rep 2006; 55:589-592.
5. Resino S, Resino R, Maria Bellon J, Micheloud D, Gutièrrez MD, de Josè MI, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis 2006; 43:243-252.
6. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998; 47:1-43.
7. Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, Guarino A, et al. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS 2006; 20:207-215.
8. Giacomet V, Albano F, Starace F, de Franciscis A, Giaquinto C, Gattinara GC, et al. Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatr 2003; 92:1398-1402.
9. The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children convened by the National Pediatric and Family HIV Resource Center (NPHRC), The Health Resources and Services Administration (HRSA), and the National Institutes of Health (NIH). 2006 Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Bethesda, MD: National Institutes of Health; 2006. http://aidsinfo.nih.gov.
10. Italian Register for Human Immunodeficiency Virus Infection in Children. Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection. Acta Pediatr 1999; 88:228-232.
11. Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, et al. Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. J Pediatr Infect Dis 2006; 25:420-426.
12. Gray L, Newell ML, Thorne C, Peckham C, Levy J, for the European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 2001; 108:116-122.
13. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39:725-731.
14. Sanchez JM, Ramos Amador JT, Fernadez de Miguel S, Gonzalez Tomee MI, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003; 22:863-867.
15. Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Giaquinto C, et al. Cancer rates significantly decrease in children with perinatal HIV infection after year 2000. J Clin Oncol 2007; 25:97-101.
16. Chiriboga CA, Fleishman S, Champion S, Gaye-Robinson L, Abrams EJ. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active antiretroviral therapy (HAART). J Pediatr 2005; 146:402-407.
17. Nachman S, Gona P, Dankner W, Weinberg A, Yogev R, Gershon A, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005; 115:e488-e494.
18. Kest H, Brogly S, McSherry G, Dashefsky B, Oleske J, Seage GR III. Malignancy in perinatally human immunodeficiency virusinfected children in the United States. Pediatric Infect Dis J 2005; 24:237-242.
19. Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, Stiller CA, Coebergh JW. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer 2006; 42:2183-2190.
20. Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, Seage GR III. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006; 296:292-300.
21. Atzori C, Clerici M, Trabattoni D, Fantoni G, Valerio A, Tronconi E, Cargnel A. Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. J Antimicro Chemother 2003; 52:276-328.
22. Armbruster C, Krugluger W, Huber M, Stephan K. Immunoglobulin G Fc(gamma) receptor expression on polymorphonuclear cells in bronchoalveolar lavage fluid of HIV-infected and HIV-seronegative patients with bacterial pneumonia. Clin Chem Lab Med 2004; 48:182-197.
23. Takahashi H, Oishi K, Yoshimine H, Kumatori A, Kumatori A, Moji K, Watanabe K, et al. Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults. Clin Infect Dis 2003; 37:1534-1540.